K-numberK250856
Device nameETEST Aztreonam/Avibactam (AZA) (0.016/4-256/4 µg/mL)
ApplicantBiomérieux
Product codeJWY
Device classClass II
Decision dateJun 12, 2025
DecisionSubstantially Equivalent
Regulation866.1640
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

ETEST Aztreonam/Avibactam (AZA) is a manual quantitative antimicrobial susceptibility test strip used to determine the minimum inhibitory concentration (MIC) of the antibiotic combination aztreonam/avibactam against Enterobacterales bacteria. The plastic strip carries a predefined antibiotic gradient that transfers into agar; bacterial growth inhibition appears as an ellipse, and the MIC is read where the ellipse intersects the strip's scale.

Technological characteristics

The device contains aztreonam at concentrations from 0.016 to 256 µg/mL overlaid with a fixed 4 µg/mL of avibactam. Key similarities to the predicate (ETEST Ceftazidime/Avibactam) include identical test methodology, inoculum type, quantitative format, and identical avibactam concentration. The primary difference is substitution of aztreonam for ceftazidime and a narrower set of indicated organisms (Enterobacterales only, excluding Pseudomonas aeruginosa and some species in the predicate).

Test standards cited

Testing followed CLSI M07-11th Edition (January 2018) broth microdilution reference method and CLSI M100 35th Edition (January 2025) specifications. The submission also adheres to the FDA Class II Special Controls Guidance Document on Antimicrobial Susceptibility Test Systems (August 28, 2009).

Substantial equivalence argument

Substantial equivalence rests on the nearly identical test platform, methodology, and performance characteristics: both use the same ETEST strip technology with identical methodology to generate MIC values. The device achieved 95.7% essential agreement and 98.0% category agreement against the CLSI reference method across 602 Enterobacterales strains, demonstrating acceptable performance comparable to the predicate's 99.1% and 99.6% respectively. Although the antimicrobial agent differs (aztreonam vs. ceftazidime), both are beta-lactam/beta-lactamase inhibitor combinations with the same avibactam concentration, intended use is functionally identical (MIC determination), and indicated organisms substantially overlap, supporting equivalence despite the narrower organism scope.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →